1. Home
  2. BLLN vs ICUI Comparison

BLLN vs ICUI Comparison

Compare BLLN & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BLLN

BillionToOne Inc.

N/A

Current Price

$92.70

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Logo ICU Medical Inc.

ICUI

ICU Medical Inc.

HOLD

Current Price

$151.76

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLLN
ICUI
Founded
2016
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.6B
IPO Year
2025
1992

Fundamental Metrics

Financial Performance
Metric
BLLN
ICUI
Price
$92.70
$151.76
Analyst Decision
Buy
Buy
Analyst Count
6
5
Target Price
$137.83
$179.50
AVG Volume (30 Days)
222.9K
245.2K
Earning Date
12-09-2025
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$254,136,000.00
$2,320,363,000.00
Revenue This Year
$98.01
N/A
Revenue Next Year
$36.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
254.30
N/A
52 Week Low
$80.00
$107.00
52 Week High
$138.70
$165.17

Technical Indicators

Market Signals
Indicator
BLLN
ICUI
Relative Strength Index (RSI) 55.02 52.99
Support Level $80.65 $148.71
Resistance Level $87.54 $154.79
Average True Range (ATR) 5.60 4.65
MACD 0.97 -0.31
Stochastic Oscillator 88.21 37.28

Price Performance

Historical Comparison
BLLN
ICUI

About BLLN BillionToOne Inc.

BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

Share on Social Networks: